Moderate-Intensity Rosuvastatin Plus Ezetimibe Versus High-Intensity Rosuvastatin for Target Low-Density Lipoprotein Cholesterol Goal Achievement in Patients With Recent Ischemic Stroke: A Randomized Controlled Trial
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Hong, Keun-Sik | - |
dc.contributor.author | Bang, Oh Young | - |
dc.contributor.author | Park, Jong -Ho | - |
dc.contributor.author | Jung, Jin-Man | - |
dc.contributor.author | Lee, Sang -Hun | - |
dc.contributor.author | Song, Tae-Jin | - |
dc.contributor.author | Nam, Hyo Suk | - |
dc.contributor.author | Park, Hee-Kwon | - |
dc.contributor.author | Jung, Keun-Hwa | - |
dc.contributor.author | Heo, Sung Hyuk | - |
dc.contributor.author | Koo, Jaseong | - |
dc.contributor.author | Yu, Kyung-Ho | - |
dc.contributor.author | Park, Kwang-Yeol | - |
dc.contributor.author | Kim, Chi Kyung | - |
dc.contributor.author | Park, Hong-Kyun | - |
dc.contributor.author | Lee, Jiyoon | - |
dc.contributor.author | Lee, Juneyoung | - |
dc.contributor.author | Seo, Woo-Keun | - |
dc.date.accessioned | 2023-09-04T07:02:24Z | - |
dc.date.available | 2023-09-04T07:02:24Z | - |
dc.date.created | 2023-08-29 | - |
dc.date.issued | 2023-05 | - |
dc.identifier.issn | 2287-6391 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/189621 | - |
dc.description.abstract | Background and Purpose Moderate-intensity statin plus ezetimibe versus high-intensity statin alone may provide a greater low-density lipoprotein cholesterol (LDL-C) reduction in patients with recent ischemic stroke. Methods This randomized, open-label, controlled trial assigned patients with recent ischemic stroke <90 days to rosuvastatin/ezetimibe 10/10 mg once daily (ROS10/EZT10) or to rosuvastatin 20 mg once daily (ROS20). The primary endpoint was LDL-C reduction ≥50% from baseline at 90 days. Key secondary endpoints were LDL-C <70 mg/dL and multiple lipid goal achievement, and composite of major vascular events. Results Of 584 randomized, 530 were included in the modified intention-to-treat analysis. The baseline LDL-C level was 130.2±34.7 mg/dL in the ROS10/EZT10 group and 131.0±33.9 mg/dL in the ROS20 group. The primary endpoint was achieved in 198 patients (72.5%) in the ROS10/EZT10 group and 148 (57.6%) in the ROS20 group (odds ratio [95% confidence interval], 1.944 [1.352–2.795]; P= 0.0003). LDL-C level <70 mg/dL was achieved in 80.2% and 65.4% in the ROS10/EZT10 and ROS20 groups (P=0.0001). Multiple lipid goal achievement rate was 71.1% and 53.7% in the ROS10/EZT10 and ROS20 groups (P<0.0001). Major vascular events occurred in 1 patient in the ROS10/EZT10 group and 9 in the ROS20 group (P=0.0091). The adverse event rates did not differ between the two groups. Conclusion Moderate-intensity rosuvastatin plus ezetimibe was superior to high-intensity rosuvastatin alone for intensive LDL-C reduction in patients with recent ischemic stroke. With the combination therapy, more than 70% of patients achieved LDL-C reduction ≥50% and 80% had an LDL-C reduction ≥50% and 80% had an LDL-C <70 mg/dL at 90 days. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | KOREAN STROKE SOC | - |
dc.title | Moderate-Intensity Rosuvastatin Plus Ezetimibe Versus High-Intensity Rosuvastatin for Target Low-Density Lipoprotein Cholesterol Goal Achievement in Patients With Recent Ischemic Stroke: A Randomized Controlled Trial | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Park, Jong -Ho | - |
dc.identifier.doi | 10.5853/jos.2022.02957 | - |
dc.identifier.scopusid | 2-s2.0-85163110654 | - |
dc.identifier.wosid | 001021497000006 | - |
dc.identifier.bibliographicCitation | JOURNAL OF STROKE, v.25, no.2, pp.242 - 250 | - |
dc.relation.isPartOf | JOURNAL OF STROKE | - |
dc.citation.title | JOURNAL OF STROKE | - |
dc.citation.volume | 25 | - |
dc.citation.number | 2 | - |
dc.citation.startPage | 242 | - |
dc.citation.endPage | 250 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.identifier.kciid | ART002963647 | - |
dc.description.journalClass | 1 | - |
dc.description.isOpenAccess | Y | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.description.journalRegisteredClass | kci | - |
dc.relation.journalResearchArea | Neurosciences & Neurology | - |
dc.relation.journalResearchArea | Cardiovascular System & Cardiology | - |
dc.relation.journalWebOfScienceCategory | Clinical Neurology | - |
dc.relation.journalWebOfScienceCategory | Peripheral Vascular Disease | - |
dc.subject.keywordPlus | LDL-CHOLESTEROL | - |
dc.subject.keywordPlus | STATIN THERAPY | - |
dc.subject.keywordPlus | EFFICACY | - |
dc.subject.keywordPlus | METAANALYSIS | - |
dc.subject.keywordPlus | MANAGEMENT | - |
dc.subject.keywordPlus | SAFETY | - |
dc.subject.keywordPlus | IDENTIFICATION | - |
dc.subject.keywordPlus | PREVENTION | - |
dc.subject.keywordPlus | GUIDELINES | - |
dc.subject.keywordPlus | INHIBITOR | - |
dc.subject.keywordAuthor | Stroke | - |
dc.subject.keywordAuthor | LDL cholesterol | - |
dc.subject.keywordAuthor | Rosuvastatin | - |
dc.subject.keywordAuthor | Ezetimibe | - |
dc.subject.keywordAuthor | Target goal | - |
dc.identifier.url | https://j-stroke.org/journal/view.php?doi=10.5853/jos.2022.02957 | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
222, Wangsimni-ro, Seongdong-gu, Seoul, 04763, Korea+82-2-2220-1365
COPYRIGHT © 2021 HANYANG UNIVERSITY.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.